Effects of long‐term azithromycin therapy on airway oxidative stress markers in non‐cystic fibrosis bronchiectasis
- 23 September 2013
- journal article
- research article
- Published by Wiley in Respirology
- Vol. 18 (7), 1056-1062
- https://doi.org/10.1111/resp.12130
Abstract
To explore the effect of long-term therapy with azithromycin in regards to airway oxidative stress markers in exhaled breath condensate (EBC) of adult patients with stable non-cystic fibrosis (CF) bronchiectasis. Open-label prospective study of 30 patients randomized to azithromycin 250 mg three times per week during 3 months (16 patients) or control (14 patients). Primary outcome were changes in nitric oxide, 8-isoprostane, pH, nitrites and nitrates in EBC. Secondary outcomes were changes in exacerbation rates, dyspnoea (Borg scale), sputum volume (cc), sputum colour (15-point scale), bacterial infection, health-related quality of life (St George's Respiratory Questionnaire), lung function and radiological extension. Azithromycin produced a significant decrease in sputum volume (8.9 (1.8) mL vs 2.1 (3.4) mL) and number of exacerbations (0.1 (0.6) vs 1.2 (0.9)). Dyspnoea (0.4 (0.1) vs 0.1 (0.2)) and health-related quality of life also improved after therapy. However, oxidative stress markers in EBC, systemic inflammatory markers as well as functional respiratory tests did not differ from the control group after therapy. A post-hoc analysis comparing patients infected or not with Pseudomonas aeruginosa revealed that these effects were more pronounced in infected patients. In this subgroup, treatment was followed by a significant reduction in sputum volume, number of exacerbations, dyspnoea and St George's Respiratory Questionnaire total score. Of all airway oxidative stress markers, only nitrates in EBC were reduced after therapy. Long-term azythromicin treatment has some clinical benefits in patients with non-CF stable bronchiectasis, but it does not affect airway oxidative stress markers.Keywords
This publication has 33 references indexed in Scilit:
- Azithromycin and the Risk of Cardiovascular DeathThe New England Journal of Medicine, 2012
- Azithromycin for Prevention of Exacerbations of COPDThe New England Journal of Medicine, 2011
- Bronchial and peripheral airway nitric oxide in primary ciliary dyskinesia and bronchiectasisRespiratory Medicine, 2009
- Exhaled 8-isoprostane and prostaglandin E2 in patients with stable and unstable cystic fibrosisFree Radical Biology & Medicine, 2008
- Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanismsEuropean Respiratory Journal, 2008
- Exhaled Breath Condensate 8-Isoprostane, Clinical Parameters, Radiological Indices and Airway Inflammation in COPDRespiration, 2007
- Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trialThorax, 2006
- Erythromycin exerts in vivo anti‐inflammatory activity downregulating cell adhesion molecule expressionBritish Journal of Pharmacology, 2005
- Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trialThorax, 2002
- Nitrite levels in breath condensate of patients with cystic fibrosis is elevated in contrast to exhaled nitric oxideThorax, 1998